MedTrace Logo

Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer

NCT00954278 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-11-15

No results posted yet for this study

Summary

The purpose of this study is to determine the number of patients with advanced, relapsed non-small cell lung cancer who can tolerate dose escalation sorafenib from 400 mg twice daily to either 600 mg twice daily or 800 mg twice daily. Safety and tolerability of sorafenib will also be examined.

Conditions

  • Carcinoma, Non Small Cell Lung

Interventions

DRUG

sorafenib

sorafenib (400mg or 600mg or 800mg) by mouth twice daily, for 28 days

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Anne M Traynor, M.D. · University of Wisconsin, Madison

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-28
Primary Completion
2015-12-23
Completion
2015-12-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00954278 on ClinicalTrials.gov